Created with Highcharts 9.0.1
Chart context menu
Numbers
© DRUGANALYST 2025
BUY
HOLD
SELL
US Sales
DrugAnalyst Database
DRUGANALYST LTD
172 TOTTENHAM COURT RD
LONDON W1T 7NS
+44 20 3696 7500
Log In
This site is best viewed with JavaScript enabled
Company
Sector
Drugs
Valuation
Changes
Share Prices
Portfolio
Get Access
European Pharma
Argenx
Ascendis
AstraZeneca
Bayer
Genmab
Glaxo
Ipsen
Lundbeck
Novartis
Novo Nordisk
Roche
Sanofi
UCB
US Pharma
AbbVie
Alnylam
Amgen
Biogen
BioMarin
Bristol
Gilead
Incyte
Jazz
JnJ
Lilly
Merck
Moderna
Pfizer
Regeneron
Teva
Vertex
Asia Pacific Pharma
Astellas
Chugai
Daiichi
Eisai
Shionogi
Takeda
Dibdobs
Merck KGaA
Sage
Neurocrine
Ultragenyx
Sarepta
Cytokinetics
Acadia
BioCryst
Pacira
Amicus
Numbers only
Dogbasket BUY
close
Peer Comparison
Total Revenue
Pharma Sales
COGS
SG&A
R&D
Gross Margin
SG&A Margin
R&D Margin
Trading Profit
TPMeR&D Margin
Trading Margin
Tax Rate
Net Income
GAAP Net Margin
Core Net Margin
Incremental Margin
Net Cash/Debt to Equity Ratios
Per Employee Metrics
Growth - CAGRs
Drug Sales Expectation Change
Core Adjustments
Net Debt / EBITDA Ratios
Dividend Yield
Revenue High/Low Analysis
Net Profit High/Low Analysis
Receivables Outstanding
Sector P&L
EU Major
US Major
Japanese
US Big Biotech
* Upgrades / Downgrades
Price Performance
Sector Performance Charts
R&D
R&D Pipeline
close
Drugs
Biggest Drugs
Biggest Pipeline Drugs
Growers
Decliners
Upgrades
Downgrades
High/Low Analysis
US Exposure
Drug List
Therapeutics & Mechanisms by 2029 Sales
ANTICANCER - $207,426m
Anti-PD1/PD-L1
Anti-CD20 mAb
Anti-CDK
Anti-CD38
Anti-HER2
Anti-VEGF mAb
RTK inhibitor
BTK-inhibitor
CAR-T
Androgen inhibitors
PARP
TYK2-inhibitor
Anti-TIGIT
Cereblon E3
TYPE-2 DIABETES - $191,117m
GLP-1
Insulin analogue
SGLT2
DPP-4
IMMUNOLOGY - $87,263m
Anti-IL-17/23
JAK Inhibitor
Anti-TNF
Anti-IL-6
VACCINES - $26,660m
Pneumonia vaccine
COVID vaccine
RSV vaccine
Flu vaccine
mRNA cancer vaccine
OTHER
CGRP
Anti-FcRN MAb
Anti-PCSK9
Xa inhibitors
Beta-amyloid
HIV
Obesity
More...
close
Valuation Summary
Summary Sheet
close
Valuation Metrics
DA-NET
P/E
GAAP P/E
P/S
PEG
Consensus Target Prices
Shareprice Volatility
Account
Change Password
Email Preferences
Other
Shareprice Summary
Reporting Heatmap
Share Price Movers
Single Drug Snapshot
Medicare Negotiation
Dividend Stripping (AC/DC)
Custom Models
DA STAFF PORTFOLIOS
close
Your Client Rank:
Loading...
8
9
8
9
Updated 20-May-2025
JnJ
Balversa
Chart
Sales
Snapshot
QoQ
T&Ds
Alerts
US Label
Marketed
FGFR kinase inhibitor
Bladder Cancer
Loading quarterly data...
Consensus
Lower than Low
Lower than Median
Equal
Higher than Median
Higher than High
Actual (No Consensus)
Excel
Median
YOY
High
Low
US
YOY
RoW
YOY
Balversa is also known as erdafitinib and JNJ-493.
Excel Plugin ID: DRUG-1671
